glp-1 obesity drug news oct 21 2025 Why drugs are changing the future of metabolic health Drugmakers are racing to find

Phase 2: Provider Medical Review, Evaluation, and Prescribing Decision Provider Credentials and Review Process : According to ro.co disclosures, licensed healthcare providers affiliated with Ro-contracted physician practices review submitted assessments

Karacabeyli D, Lacaille D

Effectiveness of liraglutide 3.0 mg treatment on weight regain after bariatric surgery in severely obese patients

These may include: Nausea, vomiting or diarrhoea (most common early on) Constipation Fatigue Mild increases in heart rate (similar to changes seen with GLP-1 medicines) Side effects were more frequent at higher doses (8 mg and 12 mg), but still rated mild to moderate overall